Table 5.
Drug related adverse events during all treatment courses all treated patients
| Grade | 40 mg | 20 mg | ||
|---|---|---|---|---|
| n = 5 | n = 28 | |||
| 1/2 | 3/4 | 1/2 | 3/4 | |
| Elevated triglycerides | 1 | 0 | 17 | 0 |
| Fatigue | 3 | 2 | 15 | 1 |
| Dermatitis | 3 | 2 | 15 | 1 |
| Pruritus | 3 | 0 | 13 | 1 |
| Nausea | 2 | 0 | 13 | 0 |
| Dry Skin | 1 | 0 | 11 | 0 |
| Myalgias | 2 | 1 | 11 | 0 |
| Dry Mouth | 0 | 0 | 8 | 0 |
| Arthralgia | 3 | 1 | 7 | 0 |
| Anorexia | 1 | 0 | 6 | 0 |
| Diarrhea | 1 | 0 | 6 | 0 |
| Headache | 4 | 0 | 6 | 0 |
| AST increase | 2 | 0 | 3 | 2 |
| Vomiting | 1 | 0 | 4 | 0 |
| Back pain | 0 | 0 | 4 | 0 |
| Taste disturbance | 0 | 0 | 4 | 0 |
| ALT increase | 0 | 0 | 3 | 0 |
| Weakness | 0 | 0 | 3 | 0 |
| Alopecia | 3 | 0 | 2 | 0 |
| Thrombosis/PE | 0 | 2a | 0 | 2b |
| Dyspepsia | 0 | 0 | 2 | 0 |
| Pain in limb | 0 | 0 | 2 | 0 |
| Pancreatitis | 0 | 0 | 0 | 1 |
| Leukopenia | 1 | 0 | 1 | 0 |
| Constipation | 2 | 0 | 0 | 0 |
| Rigors | 2 | 0 | 0 | 0 |
aOne patient experienced vena caval embolism and the other developed DVT
bOne patient developed PE in Phase 1 and the other DVT in Phase 2